Emergent BioSolutions Inc
NYSE:EBS

Watchlist Manager
Emergent BioSolutions Inc Logo
Emergent BioSolutions Inc
NYSE:EBS
Watchlist
Price: 11.91 USD 1.71% Market Closed
Market Cap: $625.5m

Net Margin

9.6%
Current
Improving
by 43.6%
vs 3-y average of -34%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
9.6%
=
Net Income
$75.9m
/
Revenue
$788.9m

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
9.6%
=
Net Income
$75.9m
/
Revenue
$788.9m

Peer Comparison

Country Company Market Cap Net
Margin
US
Emergent BioSolutions Inc
NYSE:EBS
629.2m USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
393.1B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
185.9B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
172.7B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
120.7B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.5B USD
Loading...
AU
CSL Ltd
ASX:CSL
88.1B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43.4B EUR
Loading...
US
Seagen Inc
F:SGT
39.3B EUR
Loading...

Market Distribution

In line with most companies in the United States of America
Percentile
66th
Based on 15 072 companies
66th percentile
9.6%
Low
-4 418 600% — -9.6%
Typical Range
-9.6% — 11.3%
High
11.3% — 1 135 400%
Distribution Statistics
the United States of America
Min -4 418 600%
30th Percentile -9.6%
Median 3.1%
70th Percentile 11.3%
Max 1 135 400%

Emergent BioSolutions Inc
Glance View

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. The company is headquartered in Gaithersburg, Maryland and currently employs 2,416 full-time employees. The company went IPO on 2006-11-15. The firm is focused on five PHT categories: chemical, biological, radiological, nuclear and explosives (CBRNE); emerging infectious diseases; travel health; public health crises (such as the opioid crisis and the COVID-19 pandemic); acute, emergency, and community care. Its business lines include Medical Countermeasures (MCM), Commercial and CDMO. MCM focuses primarily on procurement of MCM products and procured product candidates by domestic and international government customers. The company provides solutions for public health threats through a portfolio of vaccines and therapeutics that it develops and manufactures for governments and consumers. The firm also offers a range of integrated contract development and manufacturing services for pharmaceutical and biotechnology customers.

EBS Intrinsic Value
19.82 USD
Undervaluation 40%
Intrinsic Value
Price
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
9.6%
=
Net Income
$75.9m
/
Revenue
$788.9m
What is Emergent BioSolutions Inc's current Net Margin?

The current Net Margin for Emergent BioSolutions Inc is 9.6%, which is above its 3-year median of -34%.

How has Net Margin changed over time?

Over the last 3 years, Emergent BioSolutions Inc’s Net Margin has increased from 3.5% to 9.6%. During this period, it reached a low of -77.4% on Sep 30, 2023 and a high of 16.4% on Jun 30, 2025.

Back to Top